For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Oyster Point Pharma, Inc.

USPTO Granted Patents = 18

EPO Patents = 6

Trademarks = 9

Forward Citations = 67

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

James Donald Loudin (11 out of 45 patents)

Kenneth Jason Mandell (11 out of 20 patents)

Douglas Michael Ackermann, Jr (7 out of 37 patents)

4. Douglas Michael Ackermann (4 out of 34 patents)

5. Srinivasa Rao Akireddy (4 out of 14 patents)

6. Balwinder Singh Bhatti (4 out of 43 patents)

7. Timothy J Cuthbertson (4 out of 8 patents)

8. Craig Harrison Miller (4 out of 37 patents)

9. Joseph Pike Mitchener, Jr (4 out of 7 patents)

10. Julio A Munoz (4 out of 20 patents)

11. Pieter Albert Otten (4 out of 7 patents)

12. Gary Maurice Dull (4 out of 86 patents)

13. Jeffrey Alan Nau (3 out of 3 patents)

14. George J Donato (3 out of 3 patents)

15. John K Lokhnauth (2 out of 2 patents)

18 patents: Sort by Forward Citations

1. D1055277 - Nasal spray guide (2024-12-24),

2. D1055276 - Nasal spray guide (2024-12-24),

3. 12098018 - Nesting structures for storage, transport, and assembly of drug dispensers and containers (2024-09-24),

4. 11911380 - Compositions and use of varenicline for treating dry eye (2024-02-27),

5. 11903943 - Compositions and use of varenicline for treating dry eye (2024-02-20),

6. 11903942 - Compositions and use of varenicline for treating dry eye (2024-02-20),

7. 11903941 - Compositions and use of varenicline for treating dry eye (2024-02-20),

8. 11542253 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2023-01-03),

9. 11224598 - Methods of increasing lacrimal proteins (2022-01-18),

10. 10919879 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2021-02-16),

11. 10709707 - Methods of treating ocular conditions (2020-07-14),

12. 10456396 - Dry eye treatments (2019-10-29),

13. 10421745 - Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2019-09-24),

14. 9981949 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2018-05-29),

15. 9597284 - Dry eye treatments (2017-03-21),

Oyster Point Pharma, Inc. is a clinical-stage pharmaceutical company. They focus on discovering and developing therapies to treat ocular surface diseases. Their goal is to improve the lives of patients with dry eye disease, blepharitis, and other ocular surface disorders. Through their innovative approach, they aim to provide effective and safe treatments for these conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#49 in Princeton, NJ

#672 in New Jersey

#17,417 in US

#33,187 in the World

Princeton, NJ, United States of America

Oyster Point Pharma, Inc.

Forward Citations = 67

19 inventors:

James Donald Loudin (11 out of 45 patents)

Kenneth Jason Mandell (11 out of 20 patents)

Douglas Michael Ackermann, Jr (7 out of 37 patents)

4. Douglas Michael Ackermann (4 out of 34 patents)

5. Srinivasa Rao Akireddy (4 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…